Precision oncology has transformed who receives treatment and what biology we target. The next frontier is designing where therapeutic activity occurs.
- Crossing The Uncrossable: Skin Biology For The Delivery Of Peptide And Protein Therapeutics
- When The Adhesive Becomes The Drug Delivery System
- Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan
- Drug–Device Combination Products: Bridging Formulation, Device, And Manufacturing Decisions
- Rethinking Drug Delivery To Combat Antibiotic Resistance
- The Resurgence Of Fervor For Oral Delivery
- Advancing Multi-Pathology Disease-Modifying Therapy For Neurodegenerative Diseases
- Container Closure Systems For Biosimilars: Is There Regulatory Difference?
ON-DEMAND WEBINARS
Review the EU Medical Device Regulation (MDR) changes, specifically with respect to integral combination products, and examine the technical documentation packages supporting functionality and content.
Explore the role of solid form services in helping meet accelerated timelines of the drug development lifecycle along with examples of robust workflows for fast and thorough solid form screens.
Process parameter and quality attribute relationships, including those for typical pre- and post-ASD unit operations, will be explored in the context of real-world examples.
Gain valuable insights into the jet milling process and Quality by Design approach for inhalation drug delivery and their potential applications in drug development.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![West-Labs 093_ASE-0111]( "Establishing And Safeguarding Shelf Life In Combination Products")
Establishing And Safeguarding Shelf Life In Combination ProductsEstablishing combination product shelf life requires aligning stability. Holistic, data-driven stability studies ensure product function, safety, and label claims through the entire supply chain.
-
![Scientists Mixing Solution In Lab GettyImages-1443286944]( "Formulation Development For Injectables")
Formulation Development For InjectablesA uniquely modified cyclodextrin is emerging as a versatile and indispensable tool for development. Explore how the right formulation approach can enhance drug delivery and improve patient outcomes.
-
![nanoparticles_updated]( "Liposome Vs. Lipid Nanoparticle: What's The Difference?")
Liposome Vs. Lipid Nanoparticle: What's The Difference?Here, we discuss the differences between nanoparticles and liposomes along with their applications in medicine.
-
![GettyImages-851771510-eye-futuristic-scanning]( "Ophthalmic Drug Delivery")
Ophthalmic Drug DeliveryExplore the challenges to effective delivery of drugs to the eye, intricacies of ophthalmic drug delivery, and advantages of nanoparticles as an enabling technology for ocular drug-delivery systems.
-
![autoinjectables-clinical-GettyImages-2197657107]( "MIDBA: A New Regulatory Approach To Clinical Device Bridging")
MIDBA: A New Regulatory Approach To Clinical Device BridgingWhen devices evolve, evidence expectations can shift. Explore a risk-based clinical bridging approach to support regulatory decisions.
-
![Artificial Intelligence (AI) Digital Concept GettyImages-1160995648]( "The Algorithm Is In: 5 Ways AI Is Transforming Medicine")
The Algorithm Is In: 5 Ways AI Is Transforming MedicineAI is transforming the medical field, offering innovative solutions to complex problems. Explore the potential of AI in revolutionizing healthcare and leveraging data to improve patient experiences.
-
![capture1]( "Responding To Trends In Prefilled Delivery: Component Assessment And Selection")
Responding To Trends In Prefilled Delivery: Component Assessment And SelectionExisting plunger technology for PFS was developed for manual injection and does not meet the evolving requirements for drug delivery especially for consistency of injection rate.
-
![West-vials]( "Low Temperature Storage Containment For Vial And Syringe Systems")
Low Temperature Storage Containment For Vial And Syringe SystemsWith the growth of advanced therapy medicinal products, there is an increased need for specialized low-temperature packaging solutions, particularly for vials and syringe systems at -50°C to ≤ -130°C.
-
![DD 3 - PFS Grouping 002]( "Lifecycle Planning For Containment And Delivery Of Biologics Drug Products")
Lifecycle Planning For Containment And Delivery Of Biologics Drug ProductsRead more about trends in the biologics market that could impact the lifecycle strategies for your drug product and steps you can take around drug packaging early in development.
-
![GettyImages-1334686671-cold-chain-cryopreservation-logistics]( "Overcoming The Challenge Of Maintaining Sterility At Low Temperature Storage")
Overcoming The Challenge Of Maintaining Sterility At Low Temperature StorageLearn about a biotech company with a recently approved gene therapy product that needed to select a packaging solution to meet their needs for storage at low temperatures and still get to market quickly.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.
DELIVERED BY DEGRAZIO
-
![Delivered _by _DeGrazio_Logo_Color_2]( "Container Closure Systems For Biosimilars: Is There Regulatory Difference?")
Container Closure Systems For Biosimilars: Is There Regulatory Difference?In this article, Fran DeGrazio discusses the FDA’s draft guidance on container closure systems for biosimilar products. She highlights key takeaways and offers recommendations on implications that developers of biosimilar pharmaceutical products should consider in areas such as quality, testing, and documentation.
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts.
